Daily Ards Research Analysis
Analyzed 3 papers and selected 3 impactful papers.
Summary
A large multicenter registry of head and neck cancer patients with COVID-19 identified ARDS, sepsis, chemotherapy, and hospitalization as key mortality drivers, while vaccination was protective. An obstetric study found that PlGF and the sFlt-1/PlGF ratio robustly predict adverse perinatal outcomes in early-onset SGA/FGR, with limited incremental value from fetal Doppler. A critical commentary emphasizes incorporating comorbidity profiles when interpreting COVID-19 ARDS microcirculation data.
Research Themes
- COVID-19 outcomes in oncology populations
- Angiogenic biomarkers for perinatal risk prediction
- Methodological rigor in ARDS microcirculation research
Selected Articles
1. An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).
In a multicenter registry of 403 head and neck cancer patients with COVID-19, all-cause mortality was 18.8%, with 21 COVID-attributed deaths. Multivariable models showed ARDS (OR 11.64), sepsis (OR 8.99), chemotherapy (OR 28.08), and hospitalization (OR 7.32) increased mortality risk, while vaccination was protective (OR 0.29). Cluster analysis highlighted 20 determinants including COPD, coagulopathy, and ARDS.
Impact: This is the largest dedicated cohort analyzing COVID-19 outcomes in head and neck cancer, providing robust, cancer-specific mortality determinants and quantifying the protective effect of vaccination.
Clinical Implications: Risk stratification for HNC patients with COVID-19 should account for ARDS, sepsis, and ongoing chemotherapy, and prioritize vaccination. Findings support proactive monitoring and early escalation in high-risk profiles.
Key Findings
- All-cause mortality was 18.8% (76/403); 21 deaths were attributed to COVID-19.
- ARDS (OR 11.64), sepsis (OR 8.99), chemotherapy (OR 28.08), and hospitalization (OR 7.32) independently increased mortality risk.
- Vaccination reduced risk of death (OR 0.29).
- Unsupervised clustering identified 20 determinants including COPD, coagulopathy, heart failure, ARDS, and treatment modifications.
Methodological Strengths
- Multicenter observational registry with n=403 spanning 2019–2022
- Multivariable modeling and unsupervised cluster analysis to handle multiple covariates
Limitations
- Observational design limits causal inference and is subject to residual confounding
- Heterogeneity in treatments and care settings; attribution of cause of death may be imperfect
Future Directions: Prospective validation of risk models, incorporation of time-updated exposures (e.g., treatment changes), and intervention studies targeting high-risk clusters.
BACKGROUND: We aimed to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with head and neck cancer (HNC). METHODS: The HERODOTUS registry is a multicenter observational study which included patients with any HNC and a COVID-19 diagnosis. Clinical data were extracted from medical records of patients from 3/2019 until 12/2022. As the study involved numerous variables that would possibly overlap, a cluster analysis was performed for the prediction of patient death due to COVID-19. RESULTS: Among 403 COVID-19 positive cases, 76 patients died (all-cause fatality rate 18.8%) ;21 deaths were attributed to COVID-19. On multivariate analysis, poor performance status (OR: 8.96, 95% CI: 2.07-47.86), development of sepsis (OR:8.99, 95% CI:1.48-72.4) or ARDS (OR:11.64, 95% CI:2.53--64.42), administration of chemotherapy (OR: 28.08, 95% CI: 5.49-158.92) and hospitalization (OR:7.32, 95% CI: 2.49-23.3) had a negative impact on survival, whereas vaccination was protective (OR: 0.29, 95% CI: 0.11-0.75). The clustering procedure resulted in the automated creation of four clusters and identified the following determinants of death: COPD, autoimmune disease, squamous/adenocarcinoma histology, disease stage, fever, diarrhea, fatigue, first line immunotherapy/immunochemotherapy, second line chemotherapy/cetuximab, cisplatin, chemoradiation, ARDS, coagulopathy, heart failure, treatment modifications due to COVID-19, surgical complications and vaccination. CONCLUSIONS: This is the largest cohort of patients with HNC and COVID-19. All-cause fatality rate in patients with HNC and COVID-19 was approximately 19%. Among 41 covariates with discriminatory power analyzed, 20 were identified as major determinants of death. Vaccination was protective against death from COVID-19.
2. Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia.
In 469 early-onset SGA/FGR pregnancies, PlGF and the sFlt-1/PlGF ratio showed strong predictive performance for composite adverse perinatal outcomes and subsequent pre-eclampsia. Adding fetal Doppler to PlGF modestly reduced false positives but did not significantly improve sensitivity or outperform PlGF alone.
Impact: The study refines risk prediction beyond pre-eclampsia status, showing angiogenic biomarkers maintain high performance and clarifying the limited incremental value of Doppler.
Clinical Implications: Integrating PlGF and sFlt-1/PlGF into assessment of early SGA/FGR can improve triage and timing of surveillance/delivery; Doppler may help reduce false positives but should not replace biochemical markers.
Key Findings
- Among 469 early-onset small fetuses, CAPO occurred in 46.5% and PE was present at diagnosis in 15.8% and developed later in 17.7%.
- PlGF alone predicted CAPO with AUC 0.862 (95% CI 0.828–0.895); PlGF + Doppler AUC 0.866 (95% CI 0.833–0.899) without significant improvement (P=0.621).
- In non-PE pregnancies, PlGF was the best single predictor (AUC 0.797), while in PE pregnancies the sFlt-1/PlGF ratio performed best (AUC 0.802).
- For predicting subsequent PE, the sFlt-1/PlGF ratio achieved AUC 0.861, with no added value from Doppler.
Methodological Strengths
- Single-center cohort with a sizeable sample (n=469) and prespecified biomarker/Doppler combinations
- Robust discrimination analyses (AUC with 95% CI) and stratification by PE status
Limitations
- Retrospective single-center design limits generalizability and causal inference
- Potential selection bias and lack of external validation; incomplete Doppler data may affect combined models
Future Directions: Prospective multicenter validation, integration into risk-based care pathways, and evaluation of clinical impact and cost-effectiveness.
OBJECTIVES: To assess the predictive performance of angiogenic factors and fetal Doppler, alone and in combination, for composite adverse perinatal outcome (CAPO) in early-onset small-for-gestational age (SGA) and fetal growth restriction (FGR), in cases both with and without pre-eclampsia (PE), in order to evaluate the ability of these markers to predict adverse outcomes beyond their established association with PE and to better delineate the specific contribution of PE to their predictive value. METHODS: This was a retrospective observational study conducted at Vall d'Hebron University Hospital, Barcelona, Spain, between January 2016 and January 2022. The study population included singleton pregnancies with an estimated fetal weight < 10 RESULTS: Overall, 469 women with an early-onset small fetus were included. PE was present at diagnosis in 74/469 (15.8%) cases and developed later in 83 (17.7%) cases. CAPO occurred in 46.5% of cases. In the overall cohort, PlGF combined with fetal Doppler findings showed the highest predictive performance for CAPO (AUC, 0.866 (95% CI, 0.833-0.899)), outperforming fetal Doppler alone. Notably, the performance of the combined model was not significantly different from PlGF alone (AUC, 0.862 (95% CI, 0.828-0.895); P = 0.621). These findings were consistent in pregnancies without PE, in which PlGF remained the best-performing single predictor of CAPO (AUC, 0.797 (95% CI, 0.740-0.854)). In pregnancies with PE at any time, the best-performing single predictor was the sFlt-1/PlGF ratio (AUC, 0.802 (95% CI, 0.728-0.876)). For the prediction of subsequent PE after enrolment, the sFlt-1/PlGF ratio alone (AUC, 0.861 (95% CI, 0.821-0.901)) and in combination with fetal Doppler (AUC, 0.862 (95% CI, 0.822-0.902)) achieved the highest predictive performance. Combining fetal Doppler findings with angiogenic factors reduced false-positive rates, but did not improve sensitivity. CONCLUSION: This study confirmed the robust predictive performance of PlGF and the sFlt-1/PlGF ratio for identifying CAPO and PE in early-onset SGA/FGR. The predictive value of PlGF and fetal Doppler remained consistent irrespective of PE status, while the sFlt-1/PlGF ratio showed reduced predictive accuracy in non-PE pregnancies, but still outperformed Doppler. These findings support the integration of angiogenic factors into the clinical assessment of early-onset SGA/FGR, for both cases with and those without PE. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
3. Interpreting COVID-19 ARDS microcirculation findings: Why comorbidity data matter.
This commentary argues that comorbidities and baseline cardiovascular risk must be systematically reported and adjusted for when interpreting COVID-19 ARDS microcirculation findings. Without comorbidity stratification, microvascular abnormalities may be misattributed to COVID-19 rather than underlying disease burden.
Impact: It provides a methodologic framework to reduce confounding in ARDS microcirculation studies, potentially improving the validity of future research and meta-analyses.
Clinical Implications: Encourages standardized comorbidity capture (e.g., Charlson index), pre-specified subgroup analyses, and multivariable adjustment to enhance interpretability of bedside microcirculatory monitoring in COVID-19 ARDS.
Key Findings
- Microcirculatory abnormalities in COVID-19 ARDS may be confounded by underlying comorbidities if not properly stratified.
- Recommends standardized comorbidity reporting and adjustment to improve study validity.
- Highlights the risk of misattribution of microvascular changes to COVID-19 without accounting for baseline disease burden.
Methodological Strengths
- Clear methodological critique with practical recommendations for confounding control
- Focuses on standardization and transparency to enhance reproducibility
Limitations
- No original data; conclusions are based on methodological reasoning
- Recommendations are not empirically tested within this work
Future Directions: Prospective ARDS microcirculation studies with pre-registered analysis plans incorporating comorbidity indices and stratification, enabling robust meta-analyses.